Abstract:Diagnostic bone marrow (BM) DNA and matched plasma-derived circulating tumour DNA (ctDNA) demonstrated excellent correlations in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML),1-4 and dynamic ctDNA monitoring contributes to predict relapse in MDS and AML patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).5 However, few researches are reported on the application of ctDNA dynamic monitoring assessments during the whole disease course in MDS and AML.1 Here, we assessed the feasibility and utility of ctDNA as a novel and minimally invasive biomarker based on targeted next-generation sequencing (NGS) to monitor treatment outcome, track clonal evolution and predict survival. To the best of our knowledge, we firstly demonstrated the application of ctDNA concentration as an effective prognostic biomarker in MDS and AML. The details of clinical data and methods are shown in Tables S1–S3. Thirty-five adult patients were involved in our study. Twenty-seven patients had pre- and post-treatment plasma-derived ctDNA, and paired baseline BM DNA NGS assessments were included for both concordance analysis and dynamic ctDNA analysis. Four patients with only baseline BM DNA and plasma-derived ctDNA NGS assessments were used for concordance analysis. Three patients with only pre- and post-treatment ctDNA assessments and one patient with only post-treatment ctDNA assessments were used for dynamic ctDNA analysis (Figure 1). A total of 46 mutated genes with 135 mutations were detected in BM DNA and plasma-derived ctDNA, involving 42 genes with 100 mutations (74.1%) detected both in BM DNA and plasma-derived ctDNA (Figure 2A, Figure S1). Among the 100 concordant mutations, the concordance of variant allele frequencies (VAFs) assessment based on plasma and BM was high (R = .854 p < .001) (Figure 2B). Comparing pre-treatment mean ctDNA concentrations with blasts in BM at baseline measured by cytological analysis, we found pre-treatment mean ctDNA concentrations were strongly associated with BM blasts at baseline (R = .618, p < .001) (Figure 2C), indicating mean ctDNA concentration were related to tumour burden. We also reached a moderate correlation between pre-treatment mean ctDNA VAF and BM blasts (R = .533, p = .001) (Figure S2). For patients with pre- and post-treatment paired samples, dynamic change of VAFs was analyzed. Patients were segregated into three groups, including those achieved a complete response (CR), those with CR with incomplete hematologic recovery (CRi) (for AML), morphologic CR (mCR) (for MDS)/morphologic leukaemia-free state (mLFS) (for AML) or stable disease (SD) (for MDS) and those with progressive disease (PD). Sixteen patients with CR had dramatically decreased VAFs (median VAF, 16.7% pre-treatment vs. 0% post-treatment, p < .001). Persistent VAFs were observed in CRi, mCR, mLFS and SD patients (median VAF, 3.6% pre-treatment vs. 3.3% post-treatment, p = .804). VAFs from PD patients tended to increase (median VAF, 4.7% pre-treatment vs. 6.7% post-treatment, p = .053) (Figure 2D). The post-treatment VAFs were lower in patients with CR versus those without CR (median VAF, 0% vs. 3.7%, p < .001) (Figure S3A). Similarly, delta VAFs from pre-treatment to post-treatment were greater in patients with CR versus those without CR (median delta VAF, 12.8% vs. −.3%, p < .001) (Figure S3B). As expected, post-treatment ctDNA positivity was associated with both shorter progression-free survival (PFS, median PFS, 5.6 vs. not reached [NR] months, p < .001) (Figure 3A) and overall survival (OS, median OS, 11.0 vs. NR months, p < .001) (Figure 3B). In the meantime, increased mean ctDNA VAF (defined as increasing post-treatment compared with pre-treatment ctDNA VAF) predicted decreased PFS (median PFS, 2.8 vs. 25.0 months, p < .001) (Figure 3C) and OS (median OS, 8.1 vs. 16.8 months, p = .014) (Figure 3D). Furthermore, we discovered patients with increased mean ctDNA concentration have poorer PFS (median PFS, 2.8 vs. NR months, p < .001) (Figure 3E) and OS (median OS, 7.9 vs. NR months, p < .001) (Figure 3F). However, the significant prognostic impact of pre-treatment ctDNA status on PFS and OS with mean ctDNA VAF (Figure S4A,B) or mean ctDNA concentration (Figure S4C and D) was not discovered, indicating pre-treatment ctDNA status was not a good biomarker to stratify the prognosis. To investigate the prognostic differences between mean ctDNA VAF and mean ctDNA concentration change from post- to pre-treatment, we compared the discrimination ability of the prognostic model with the concordance index (C-index). The model based on mean ctDNA concentration change showed better discrimination of PFS with C-index value of .79, compared to mean ctDNA VAF with C-index value of .75. The area under curve (AUC) for predicting 1-year PFS indicated more excellent conformity based on ctDNA concentration change, compared to mean ctDNA VAF (AUC, .84 vs. .82) (Figure 3G). Similarity was also discovered in OS analysis (C-index, .70 vs. .67; AUC, .78 vs. .72) (Figure 3H). Next, we tried to explore clonal evolution patterns in refractory or relapsed MDS and AML. We observed two patterns of progression from MDS to secondary AML (sAML). Patient 1 (P1) showed a linear pattern, where successive clones occurred within the previous parental clone. The acquisition of FLT3 mutation occurred during disease relapse and subsequently transformation to AML (Figure 4A). P7 and P8 showed a branched pattern (Figure 4B, Figure S5A, respectively). For P7, the original clone harboring PTPN11 mutation was suppressed while a new clone carrying FLT3-ITD mutation expanded, leading to AML transformation. However, we only discovered one linear pattern in refractory or relapsed AML. Three representative patients (P11, P26 and P35) achieved CR and relapsed within 6−7 months (Figure 4C, Figure S5B,C, respectively). The founding clone in the primary tumour in P11 contained mutations in WT1, GATA2 and RAD21 that were all recurrent at relapse. A new subclone occurred and evolved to become the dominant clone at relapse by acquiring additional SETD2 mutations. Compared with flow cytometry measurable residue disease results, we found that ctDNA molecular residue detection was earlier about 4 months. In summary, our study revealed that serial plasma-derived ctDNA assessments can reflect treatment response, survival, and clonal evolution in adult MDS and AML as a minimally invasive method, which warrant the prospective use of ctDNA as a biomarker in disease monitoring. This work was supported by the National Natural Science Foundation of China (grant number: 81800121) and Zhejiang Medical Association Clinical Research Fund project (grant number: 2017ZYC-A14). The authors also thank all the patients who participated in this study. The authors declare that they have no competing interests. The National Natural Science Foundation of China Grant Number: 81800121; Zhejiang Medical Association Clinical Research Fund project, Grant Number: 2017ZYC-A14. The data used in the present study are available from the corresponding author upon reasonable request. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Abstract:Abstract Background: Autologous stem cell transplantation (ASCT) can be curative for a subset of patients (pts) with relapsed/refractory classical Hodgkin lymphoma (cHL). Post-ASCT maintenance therapy with brentuximab vedotin (BV) improves progression-free survival (PFS) among pts with high-risk clinical features, and PD-1 blockade is also being investigated in this setting. Ideally, novel biomarkers could be used to guide pt selection for these post-ASCT therapies. We hypothesized that the presence of minimal residual disease (MRD), quantified using immunoglobulin-based next generation sequencing (IgNGS), could predict post-ASCT relapse. As a preliminary test of this hypothesis, we analyzed a cohort of cHL pts who had serial peripheral blood mononuclear cell (PBMC) and plasma samples collected before or after ASCT. Methods: Samples from 2 cohorts (n=36) were analyzed. 28 pts were prospectively enrolled on a biobanking protocol and underwent ASCT at Dana-Farber Cancer Institute between 2014-2016 (biobank cohort). In addition, 8 pts underwent ASCT between 2015 and 2016 and subsequently participated in a multicenter phase II trial of post-ASCT pembrolizumab maintenance (PM) (trial cohort) (Armand, Blood 2020). Tumor tissue and serial post-ASCT plasma and PBMC samples were collected for all pts, and some pts also had pre-ASCT PB samples available for analysis. NGS of Ig receptor sequences (IgNGS) (clonoSEQ Ò, Adaptive Biotechnologies) was used to identify and track tumor clonotypes, as previously described (Ching, BMC Cancer 2020). MRD testing was not used for clinical decision making. Results: The 36 enrolled pts received a median of 2 lines of therapy, and 30 pts (83%) achieved a complete response (CR) on pre-ASCT positron emission tomography (PET). In total, 19 pts received post-ASCT treatment - PM (n=8, all on trial), radiation therapy (n=5), BV maintenance (n=4), and allogeneic stem cell transplantation as part of a planned tandem transplant (n=2). Among 36 enrolled pts, 12 (33%) had an identifiable clonotype (11/28 biobank and 1/8 trial). Higher rates of clonotype detection were seen in pts aged <32 (median) (56% vs 11%, p=0.012) and pts with primary refractory disease (56% vs 16%, p=0.030). With a median follow-up of 50 (range 4-75) months, there were no significant differences in PFS or overall survival among pts with and without a detectable tumor clonotype. The 12 clonotyped pts had a median of 4 (range 1-13) post-ASCT plasma and 3 (range 1-17) post-ASCT PBMC samples. Among the 4 pts who relapsed, 3 had MRD detected within plasma samples with lead times of 0, 11, and 909 days (Figure 1). The pembrolizumab trial pt had detectable MRD early after ASCT which cleared within 9 weeks of starting pembrolizumab therapy, remained undetectable for the duration of pembrolizumab treatment, and became detectable again 5 months after completing PM in conjunction with clinical relapse. All pts with detectable MRD in a post-ASCT plasma sample subsequently relapsed (100% specificity). One pt relapsed without detectable MRD, but had a long interval (312 days) from last plasma sample to relapse. IgNGS testing from PBMC samples did not correlate with clinical outcomes; only two PBMC samples had detectable MRD and both were from a pt who did not relapse. 3 pts had pre-ASCT plasma samples collected concurrently with post-salvage PET scans. One pt achieved a partial response (PR) after 2 cycles of bendamustine and BV (Benda-BV), progressive disease after 4 cycles of Benda-BV, and a CR after pembrolizumab. MRD was detected after two cycles of Benda-BV (6.52 counts per million), was rising after 4 cycles of benda-BV (8.99 counts per million) and was undetectable after pembrolizumab. The pt remains in remission after a tandem transplant. Pre-ASCT samples were MRD negative in two other pts (1 CR, 1 PR) following salvage chemotherapy, both of whom remain in remission after ASCT. Conclusions: The clonotype detection rate among pts with cHL was considerably lower than has been reported for other B-cell lymphomas, likely due to the scarcity of Reed Sternberg cells within cHL tumor samples. Novel MRD techniques for cHL should be investigated. In this pilot study, among pts with a detectable clonotype, MRD was a dynamic marker of response to different therapies and was a specific indicator of impending relapse, suggesting that additional studies of MRD in cHL are warranted. Figure 1 Figure 1. Disclosures Brown: Gilead, Loxo/Lilly, SecuraBio, Sun, TG Therapeutics: Research Funding; Invectys: Other: Data Safety Monitoring Committee Service; Abbvie, Acerta/Astra-Zeneca, Beigene, Bristol-Myers Squibb/Juno/Celgene, Catapult, Eli Lilly, Genentech/Roche, Janssen, MEI Pharma, Morphosys AG, Nextcea, Novartis, Pfizer, Rigel: Consultancy. Crombie: Roche: Research Funding; Incyte: Consultancy; Karyopharm: Consultancy; Merck: Research Funding; Abbvie: Research Funding; Bayer: Research Funding. Davids: TG Therapeutics: Consultancy, Research Funding; Verastem: Consultancy, Research Funding; Takeda: Consultancy; Surface Oncology: Research Funding; AbbVie: Consultancy; Genentech: Consultancy, Research Funding; BMS: Consultancy, Research Funding; Astra-Zeneca: Consultancy, Research Funding; MEI Pharma: Consultancy, Research Funding; Ascentage Pharma: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; Adaptive Biotechnologies: Consultancy; BeiGene: Consultancy; Celgene: Consultancy; Eli Lilly and Company: Consultancy; Janssen: Consultancy; MEI Pharma: Consultancy; Merck: Consultancy; Research to Practice: Consultancy. Jacobsen: Takeda: Consultancy; Syros: Consultancy; Janssen: Research Funding; Novartis: Research Funding; Pharmacyclics: Research Funding; Acerta: Research Funding. Jacobson: Lonza: Consultancy, Honoraria, Other: Travel support; Precision Biosciences: Consultancy, Honoraria, Other: Travel support; Kite, a Gilead Company: Consultancy, Honoraria, Other: Travel support; Axis: Speakers Bureau; Clinical Care Options: Speakers Bureau; Nkarta: Consultancy, Honoraria; Novartis Pharmaceuticals Corporation: Consultancy, Honoraria, Other: Travel support; Pfizer: Consultancy, Honoraria, Other: Travel support, Research Funding; Humanigen: Consultancy, Honoraria, Other: Travel support; AbbVie: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Other: Travel support. LaCasce: Bristol-Myers Squibb Company.: Other: Data Safetly and Monitoring. Dahi: Kite / Gilead: Membership on an entity's Board of Directors or advisory committees. Chen: Gamida: Consultancy; Incyte: Consultancy. Herrera: ADC Therapeutics: Consultancy, Research Funding; Merck: Consultancy, Research Funding; Tubulis: Consultancy; Kite, a Gilead Company: Research Funding; Seagen: Consultancy, Research Funding; Takeda: Consultancy; Gilead Sciences: Research Funding; AstraZeneca: Consultancy, Research Funding; Karyopharm: Consultancy; Genentech: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding. Armand: IGM: Research Funding; Tensha: Research Funding; Roche: Research Funding; Genentech: Consultancy, Research Funding; AstraZeneca: Consultancy; Regeneron: Consultancy; Epizyme: Consultancy; Enterome: Consultancy; Daiichi Sankyo: Consultancy; Miltenyi: Consultancy; Tessa Therapeutics: Consultancy; GenMab: Consultancy; C4: Consultancy; Kite: Research Funding; Pfizer: Consultancy; Infinity: Consultancy; Otsuka: Research Funding; Sigma Tau: Research Funding; Morphosys: Consultancy; Celgene: Consultancy; ADC Therapeutics: Consultancy; Adaptive: Consultancy, Research Funding; Affimed: Consultancy, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Merck: Consultancy, Honoraria, Research Funding.

A Personalized Whole Genome-Informed Assay Targeting Single Mutant in Circulating Tumor DNA Can Identify MRD and Predict Relapse in DLBCL

Serial Monitoring of Circulating Tumour DNA on Clinical Outcome in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.

Early Measurable Residual Disease Detection after CAR-T is Associated with Poor Outcomes in Patients with Large B-cell Lymphoma

Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)

Analytical and clinical validation of a personalized, tumor-informed circulating tumor DNA assay for minimal residual disease detection.

Abstract 1039: Individualized tumor-informed circulating tumor DNA (ctDNA) analysis for postoperative monitoring of non-small cell lung cancer (NSCLC) - the MEDAL study

Tumor-informed ctDNA assessment as a valuable prognostic and predictive biomarker in diffuse large B-cell lymphoma

Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow Based Flow Cytometry for Tracking Measurable Residual Disease (MRD) in Patients with Multiple Myeloma

Abstract 3369: Utility of ctDNA-based targeted methylation MRD assay for hematological malignancies

Enhanced detection of molecular residual disease (MRD) by tumor-informed and tumor-agnostic variants in circulating tumor DNA (ctDNA).

Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA

A Novel and Cost-Efficient Measurable Residual Disease (MRD) Detection Assay Using a Single Molecule Molecular Inversion Probe-Based Next Generation Sequencing (NGS) Assay Predicts Overall Survival in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation

Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Correlation with Outcomes in Plasma Cell and Lymphoid Malignancies

Prognostic Value of Minimal Residual Disease (MRD) Among Patients with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Minimal Residual Disease Detection By Single Cell DNA Sequencing Technology: A Feasible Approach for Clinical Application and Identification of the Landscape of MRD Clones

Minimal Residual Disease (MRD) Testing in Newly Diagnosed Multiple myeloma (MM) Patients: A Prospective Head-to-Head Assessment of Cell-Based, Molecular, and Molecular-Imaging Modalities

A Prospective Multicenter Study of Minimal Residual Disease Assessment Using a Next-Generation Immunosequencing Assay and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation

Duplex Sequencing with Patient-Specific Hybrid Capture Panels Reveals Ultra-Low Frequency Measurable Residual Disease in Pediatric Acute Myeloid Leukemia

Detection of Measurable Residual Disease (MRD) in Peripheral Blood: First Report of a Novel Microfluidic Platform in Patients with Acute Myeloid Leukemia (AML)

Analytical Validation of a Circulating Tumor DNA Assay using PhasED-Seq Technology for Detecting Residual Disease in B-Cell Malignancies